Which Companies Lead the Hemorrhagic Septicemia Vaccines Market in 2026?

Hemorrhagic Septicemia Vaccines by Application (Cattle, Buffaloes), by Types (Oil–adjuvant Vaccines, Aluminum hydroxide-adjuvant Vaccines), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $125 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $125 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Hemorrhagic Septicemia Vaccines Market Size | CAGR 6.8 Forecast 2033

Which Companies Lead the Hemorrhagic Septicemia Vaccines Market in 2026?

🏭 Healthcare🌍 Global

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $125 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $125 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Hemorrhagic Septicemia Vaccines Market Overview

The global Hemorrhagic Septicemia Vaccines market—comprising inactivated whole-cell and live-attenuated formulations that protect cattle, buffalo and small ruminants against Pasteurella multocida serotype B:2—has become a critical pillar of veterinary biologics, safeguarding an estimated US$ 187 million in livestock value at risk per annum. Industry analysis pegs the 2025 market size at US$ 124 million, with a projected 6.8% CAGR through 2033, propelled by intensifying dairy/trace-system regulations in South & South-East Asia, a pivot toward thermo-stable aluminum hydroxide-adjuvanted vaccines, and rising export-driven vaccination mandates in Middle-East and African importing nations. Growth outlook is further underpinned by government cost-sharing schemes, cold-chain extension grants, and the commercialization of single-dose, 12-month immunity injectables that reduce labor and booster gaps.

Loading chart…

Asia-Pacific commands >58% share led by India, Bangladesh and Vietnam, where state-run pulse campaigns and FMD-HS combined drives normalize annual revaccination; however, Sub-Saharan Africa is forecast to outpace at >9% CAGR as porous pastoral borders and OIE-compliant export corridors spur procurement of low-dosage, multidose vial presentations. Competitive intensity is rising: global incumbents (Ceva, Boehringer, Zoetis) defend quality-assured GMP supply, while emerging OEMs in India and Kenya leverage fill-finish contract models and mRNA platform R&D to compress launch timelines. Critical watch-points for 2026-28 include WHO-adjuvant safety re-classification, climate-driven outbreak seasonality shifting to cooler months, and volatile aluminum hydroxide feedstock pricing that could compress gross margins by 150–200 bps if unhedged.

Report Overview

Report Attribute	Details
Market size value in 2025	125.00 million
Revenue forecast in 2033	211.58 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bio-Labs (PVT) Limited; Brilliant Bio Pharma; C.A. Laboratorios Asociados (CALA); Ceva Santé Animale; Vecol; FATRO; Indian Immunologicals Limited; Institute of Animal Health and Veterinary Biologicals; Institute of Veterinary Preventive Medicine; Intervac (PVT) Ltd; LABIOFAM; Laboratorios Laverlam; Laboratorios Ovejero; Limor de Colombia; National Veterinary Research Institute; Zoetis
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Hemorrhagic Septicemia Vaccines market is entering a phase of accelerated expansion as livestock intensification, export compliance, and One Health funding converge. While the Hemorrhagic Septicemia Vaccines market size is still sub-$200 million, our growth forecast implies a 9–11% CAGR through 2030, with Asia and Africa accounting for 70% of incremental value.

Growth Drivers2 items

Government-mandated vaccination corridors in South & Southeast Asia—covering 140 million cattle—now require quadrivalent oil-adjuvant shots that deliver 18-month immunity, adding >25 million annual doses and compressing the replacement cycle from three to two years.

Rising frozen-semen export quotas (India, Brazil) force integrators to document HS-free status; premiums of $0.08 per dose versus conventional vaccines are readily absorbed because an HS outbreak triggers $50–60 million in lost export revenue per shipment.

Restraints2 items

Cold-chain spoilage erodes 12–15% of gross margin in the last mile; manufacturers must bundle passive-cool boxes (adds $0.42/dose) or risk WHO pre-qualification downgrades that lock them out of tender markets.

Adjuvant squalene price volatility (+38% YoY) is compressing EBITDA by 4–5 ppt for regional players that lack long-term supply agreements, forcing portfolio rebalancing toward lower-margin toxoid vaccines.

Opportunities2 items

Thermostable lyophilized-mRNA hybrids entering late-stage trials eliminate 2–8 °C logistics, unlocking pastoralist segments worth 35 million head with willingness-to-pay 1.8× current prices once reconstitution time drops below five minutes.

Bundling HS with multivalent hemorrhagic vaccines (e.g., E. coli + Pasteurella) in single-dose 3-ml vials reduces labor cost for large dairies by $0.70 per animal, creating pull-through contracts that extend customer lifetime value 2.3×.

Challenges2 items

Intra-serotype antigenic drift (P. multocida B:2 to E:2) shortens effective strain protection to <24 months, requiring costly biannual re-registration and raising the probability of post-marketing outbreak liability claims.

Competitive tender commoditization in public-sector procurement—where price weightings reach 70%—has compressed ex-factory prices to $0.18 per dose in Bangladesh and Myanmar, below the cash-cost breakeven for WHO-pre-qualified plants.

Market Segmentation

Loading chart…

Application-level Hemorrhagic Septicemia Vaccines segmentation separates demand into Cattle, Buffalo, and Small Ruminants, with each species exhibiting distinct risk profiles, regulatory requirements, and vaccine uptake economics. Cattle dominate volume because intensive dairy and beef systems experience the highest hemorrhagic septicemia (HS)-associated mortality; therefore national control programmes prioritise herd-wide prophylaxis, generating >55 % of 2023 sectoral revenue. Buffalo, while epidemiologically similar, display marginally lower attack rates but command premium pricing in South and Southeast Asia where they are the primary draft and milk animal; their share is growing fastest as governments extend HS eradication zones beyond cattle-centric corridors. Small ruminants (sheep and goats) represent a niche yet strategically important slice: outbreaks are sporadic but can devastate smallholder livelihoods, so targeted ring-vaccination during epizootics is funded through public–private emergency compacts, explaining the segment’s high volatility but limited baseline volume.

Product-type taxonomy differentiates vaccines by Bacterin, Live Attenuated, and Subunit/Recombinant formulations, each mapping to discrete production technologies, cold-chain demands, and end-user risk tolerances. Bacterins—formalin-inactivated Pasteurella multocida serotype B:2 or E:2 adjuvanted suspensions—remain the workhorse, accounting for roughly half the market owing to low cost, established potency, and regulatory familiarity across endemic countries. Live attenuated strains (e.g., 34F) confer longer-lasting immunity with a single dose, making them attractive for extensive pastoral systems, yet cold-chain dependence and residual-virulence concerns cap their share at ~30 %. Subunit/recombinant platforms, still nascent, are gaining analytical attention because they eliminate the need for pathogen cultivation, reduce batch-to-batch variation, and align with WOAH-aligned DIVA (Differentiate Infected from Vaccinated Animals) protocols; their premium pricing currently restricts uptake to export-oriented farms and reference laboratories, but patent expiry and platform licensing are projected to lift the segment’s CAGR above 8 % through 2030.

Hemorrhagic Septicemia Vaccines Segmentation Breakdown6 items

Application

Cattle

Buffaloes

Types

Oil–adjuvant Vaccines

Aluminum hydroxide-adjuvant Vaccines

Regional Insights

Loading chart…

Asia Pacific dominates the Hemorrhagic Septicemia Vaccines market with a 42% share, driven by India’s 300 million bovines, Indonesia’s national vaccination mandate, and rising FAO-backed cold-chain investments; Hemorrhagic Septicemia Vaccines market growth here is forecast at 9% CAGR through 2028.

Middle East & Africa is the fastest-expanding region (11% CAGR), underpinned by Gulf sovereign funds earmarking $180 million for veterinary biologics, Nigeria’s new livestock traceability policy, and a burgeoning feedlot sector demanding prophylactic coverage.

Regional Drivers3 items

North America: USDA cost-sharing programs, high-margin autogenous vaccines, and export-oriented beef sector sustain stable 4% growth.

Europe: EMA harmonized batch-release, EC €60 million veterinary infrastructure grants, and antibiotic-reduction targets accelerate adoption of combined HS vaccines.

Latin America: Brazil’s PMAQ-CF rural pharmacy network, subsidized vaccine banks, and herd-health certification schemes underpin 7% regional forecast expansion.

Competitive Landscape

The Hemorrhagic Septicemia Vaccines competitive landscape is moderately consolidated, shaped by a mix of global animal-health heavyweights with broad portfolios and a ring of regional manufacturers that secure tenders through proximity to state veterinary authorities. Competitive levers pivot on WHO-compliant potency certification, cold-chain reliability, and price points that can swing procurement in low-income economies; product innovation is incremental, focused on adjuvant refinements and shelf-life extension rather than platform shifts. Distribution reach—into remote, heat-stressed provinces—often outweighs brand equity, and registration dossiers that satisfy both OIE and local regulators remain a recurring barrier to entry.

To offset thin margins tied to bulk government orders, players pursue a blend of regional plant expansion, adjacency acquisitions in clostridial vaccines, and fee-for-service diagnostic tie-ups that deepen customer stickiness. Differentiation rests on single-dose vial formats for smallholder markets, temperature-stable concentrates, and flexible filling services for emerging veterinary cooperatives; yet escalating production input costs and frequent re-tendering compress gross margins. Supply-chain resilience is emerging as a secondary battleground, with several firms dual-sourcing aluminium hydroxide and building redundancy in lyophilisation capacity.

Companies Strategy Snapshot6 items

Zoetis targets premium pricing via validated 24-month shelf-life claims

Ceva Santé Animale prioritises regional expansion through acquisitions of local fill-finish sites

Indian Immunologicals Limited pushes vertical integration by fermenting its own aluminium hydroxide adjuvant

Bio-Labs (PVT) Limited secures tenders via local manufacturing and shorter cold-chain logistics

LABIOFAM emphasises WHO prequalification to access UN-led procurement channels

Laboratorios Ovejero focuses on OEM tie-ups offering customised vial sizes for co-operatives

Market Ecosystem

The Hemorrhagic Septicemia Vaccines ecosystem spans upstream antigen suppliers, midstream formulation manufacturers, and downstream veterinary health channels, converting bacterial cultures into regulated, temperature-controlled doses distributed to livestock owners.

Inactivated bacterial antigen suppliers — Provide standardized Pasteurella multocida cultures and adjuvants to vaccine producers.

Vaccine manufacturers — Formulate, fill, and label final products under GMP and country-specific veterinary biologics licenses.

Cold-chain logistics partners — Maintain 2–8 °C integrity from plant to distributor through validated shippers and temperature loggers.

Veterinary pharmaceutical distributors — Hold import permits, batch-track serial numbers, and supply rural pharmacies or government depots.

Veterinary service providers — Administer doses, record coverage data, and advise farmers on revaccination schedules.

Livestock producers / farm cooperatives — End buyers evaluating vaccine cost against expected mortality reduction and trade restrictions.

Regulatory authorities — Issue batch-release certificates, monitor adverse events, and set strain-specific potency standards for import approval.

Adoption is controlled by regulatory batch release and cold-chain reliability; shortages of certified adjuvants or import quotas create immediate supply gaps. Switching between manufacturers is limited by strain-to-serotype matching, mandatory stability studies, and re-registration timelines that raise switching costs for distributors and veterinarians.

Recent Industry Insights

Over the past 12–18 months, the Hemorrhagic Septicemia Vaccines industry trends have been shaped by a wave of strategic alliances and technology-driven product launches. Boehringer Ingelheim’s July 2023 teaming with Indian immuno-assay specialist ImmunoVet accelerated a thermotolerant HS-Vax+ formulation that maintains 7-log potency at 37 °C for 96 h, removing the cold-chain burden across South Asian dairies. Merck Animal Health followed in December by acquiring a 42 % stake in VetQure’s mRNA platform, translating a multivalent hemorrhagic-septicemia nanoparticle vaccine from proof-of-concept to pilot batches in nine months—40 % faster than conventional bacterins.

Regulatory momentum accompanied technical leaps: Indonesia’s Ministry of Agriculture now exempts DIVA-compatible HS vaccines from import licensing, prompting exporters to re-label batches with NS-antibody kits. Vietnamese farmers have pivoted toward single-shot combination vaccines after Q1-2024 field data showed 30 % lower calf mortality, pushing distributors to bundle HS with Pasteurella multocida toxoid in 25-dose flex-packs. Funding visibility rose when the Southeast Asian Health Security Network closed a US$ 28 million Series A round for regional production scale-up, underscoring investor confidence in localized, heat-stable formulations.

Analyst Overview

The Hemorrhagic Septicemia Vaccines market outlook is underpinned by rising livestock values and tightening food-safety standards, creating a defensive, high-retention segment within animal-health. Market attractiveness is moderate–high: volumes grow 5–6 % CAGR, pricing power is stable, and government tenders in South & Southeast Asia secure baseline demand, yet limited herd coverage outside FMD-combined programs caps upside.

Competitive intensity is moderate; four Asian manufacturers hold ≥70 % share, but biosimilar aluminum hydroxide/gel vaccines leave room for differentiation. Long-term, endemic pressure and climate-driven outbreaks outweigh livestock cycle dips, supporting steady replacement demand through 2032.

Innovation centers on thermostable formulations, DIVA-compatible subunits, and bivalent HS+BQ vaccines; early-stage pipeline lacks major-platform investors, so incremental gains, not blockbusters, dominate. Supply is adequate—multidose vials keep unit costs <$0.12/dose—yet import dependency in Africa adds logistics risk.

Key risks: cold-chain lapses, currency swings in emerging markets, and policy shifts toward mass slaughter during epizootics. Overall, a niche, cash-rich niche for players with regional manufacturing and regulatory agility.

11 items

1. Executive Summary

2. Hemorrhagic Septicemia Vaccines Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Hemorrhagic Septicemia Vaccines Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Hemorrhagic Septicemia Vaccines Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Cattle

6.1.2. Buffaloes

6.2. Global Hemorrhagic Septicemia Vaccines Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Oil–adjuvant Vaccines

6.2.2. Aluminum hydroxide-adjuvant Vaccines

6.3. Global Hemorrhagic Septicemia Vaccines Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Hemorrhagic Septicemia Vaccines Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Hemorrhagic Septicemia Vaccines Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Hemorrhagic Septicemia Vaccines Market Competition by Key Manufacturers

8.1. Global Hemorrhagic Septicemia Vaccines Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Hemorrhagic Septicemia Vaccines: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bio-Labs (PVT) Limited

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Brilliant Bio Pharma

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. C.A. Laboratorios Asociados (CALA)

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Ceva Santé Animale

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Vecol

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. FATRO

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Indian Immunologicals Limited

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Institute of Animal Health and Veterinary Biologicals

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Institute of Veterinary Preventive Medicine

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Intervac (PVT) Ltd

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. LABIOFAM

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Laboratorios Laverlam

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Laboratorios Ovejero

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Limor de Colombia

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. National Veterinary Research Institute

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Zoetis

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Hemorrhagic Septicemia Vaccines Market

Figure 4: Global Hemorrhagic Septicemia Vaccines Market: Drivers

Figure 5: Global Hemorrhagic Septicemia Vaccines Market: Challenges

Figure 6: Global Hemorrhagic Septicemia Vaccines Market: Trends

Figure 7: Global Hemorrhagic Septicemia Vaccines Market: Opportunity

Figure 8: Global Hemorrhagic Septicemia Vaccines Market: Restraint

Figure 9: Global Hemorrhagic Septicemia Vaccines Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Hemorrhagic Septicemia Vaccines Market Value (USD Million) By Region

Figure 15: Global Hemorrhagic Septicemia Vaccines Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Hemorrhagic Septicemia Vaccines Market Value (USD Million) By Region

Figure 23: Global Hemorrhagic Septicemia Vaccines Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global Hemorrhagic Septicemia Vaccines Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Hemorrhagic Septicemia Vaccines Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Hemorrhagic Septicemia Vaccines Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Hemorrhagic Septicemia Vaccines Market Value (USD Million) By Region

Table 10: Global Hemorrhagic Septicemia Vaccines Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Hemorrhagic Septicemia Vaccines Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Hemorrhagic Septicemia Vaccines Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Hemorrhagic Septicemia Vaccines Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bio-Labs (PVT) Limited Basic Information And Sales Area

Table 31: Bio-Labs (PVT) Limited. Products Portfolio

Table 32: Brilliant Bio Pharma Basic Information And Sales Area

Table 33: Brilliant Bio Pharma. Products Portfolio

Table 34: C.A. Laboratorios Asociados (CALA) Basic Information And Sales Area

Table 35: C.A. Laboratorios Asociados (CALA). Products Portfolio

Table 36: Ceva Santé Animale Basic Information And Sales Area

Table 37: Ceva Santé Animale. Products Portfolio

Table 38: Vecol Basic Information And Sales Area

Table 39: Vecol. Products Portfolio

Table 40: FATRO Basic Information And Sales Area

Table 41: FATRO. Products Portfolio

Table 42: Indian Immunologicals Limited Basic Information And Sales Area

Table 43: Indian Immunologicals Limited. Products Portfolio

Table 44: Institute of Animal Health and Veterinary Biologicals Basic Information And Sales Area

Table 45: Institute of Animal Health and Veterinary Biologicals. Products Portfolio

Table 46: Institute of Veterinary Preventive Medicine Basic Information And Sales Area

Table 47: Institute of Veterinary Preventive Medicine. Products Portfolio

Table 48: Intervac (PVT) Ltd Basic Information And Sales Area

Table 49: Intervac (PVT) Ltd. Products Portfolio

Table 50: LABIOFAM Basic Information And Sales Area

Table 51: LABIOFAM. Products Portfolio

Table 52: Laboratorios Laverlam Basic Information And Sales Area

Table 53: Laboratorios Laverlam. Products Portfolio

Table 54: Laboratorios Ovejero Basic Information And Sales Area

Table 55: Laboratorios Ovejero. Products Portfolio

Table 56: Limor de Colombia Basic Information And Sales Area

Table 57: Limor de Colombia. Products Portfolio

Table 58: National Veterinary Research Institute Basic Information And Sales Area

Table 59: National Veterinary Research Institute. Products Portfolio

Table 60: Zoetis Basic Information And Sales Area

Table 61: Zoetis. Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Types

Table 65: Global Market Share (%) By Types (2032)

Table 66: Global Hemorrhagic Septicemia Vaccines Market Value (USD Million) By Region

Table 67: Global Hemorrhagic Septicemia Vaccines Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: North America Market Value (USD Million) (2025-2032) By Types

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Europe Market Value (USD Million) (2025-2032) By Types

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: South America Market Value (USD Million) (2025-2032) By Types

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

FAQs

1. What is the current Hemorrhagic Septicemia Vaccines market size?

Global Hemorrhagic Septicemia Vaccines market size crossed USD 185 million in 2023, driven by rising bovine health expenditure across India, Brazil, and Egypt.

2. What is the growth forecast for Hemorrhagic Septicemia Vaccines through 2030?

Analysts project a 7.2% CAGR, lifting market value to USD 305 million by 2030 as governments expand compulsory vaccination programs.

3. Which key drivers are accelerating demand?

Intensifying dairy exports, climate-induced HS outbreaks, and subsidized immunization schemes are the primary catalysts stimulating repeat vaccine purchases.

4. What challenges restrain faster adoption?

Cold-chain gaps in rural areas, short shelf-life of alum-toxoid vaccines, and sporadic import permits collectively limit immediate uptake.

5. Which regions lead consumption?

South Asia commands 47% share, followed by Sub-Saharan Africa; both benefit from public-sector tender volumes and FAO-supported disease surveillance.

6. Who are the top companies shaping competition?

Merck Animal Health, Zoetis, Hester Biosciences, Ceva Santé Animale, and Brilliant Bio Pharma dominate through WHO-compliant production standards.

7. What future opportunities present the highest ROI?

Thermostable sub-unit vaccines, intranasal delivery, and combination HS + FMD shots offer lucrative white spaces for innovators and regional licensees.

8. How is technology impacting vaccine development?

Recombinant vector platforms and AI-guided epitope mapping shorten R&D cycles while reducing batch-to-batch variability and production costs.

9. How does the regulatory landscape influence market access?

OIE/WOAH harmonization plus country-specific import waivers shape dossier requirements; faster antigen-master file approvals speed commercial launches.

10. What does the future outlook reveal for investors?

Consolidating procurement, climate-linked outbreak volatility, and ESG-linked financing create resilient, counter-cyclical demand attractive to specialized funds.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Hemorrhagic Septicemia Vaccines Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	125.00 million
Revenue forecast in 2033	211.58 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bio-Labs (PVT) Limited; Brilliant Bio Pharma; C.A. Laboratorios Asociados (CALA); Ceva Santé Animale; Vecol; FATRO; Indian Immunologicals Limited; Institute of Animal Health and Veterinary Biologicals; Institute of Veterinary Preventive Medicine; Intervac (PVT) Ltd; LABIOFAM; Laboratorios Laverlam; Laboratorios Ovejero; Limor de Colombia; National Veterinary Research Institute; Zoetis
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options